Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Burosumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Approves New CRYSVITA Dosing Option for Adults with XLH
    FDA Approves New CRYSVITA Dosing Option for Adults with XLH

    14 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/14/3294921/0/en/fda-approves-new-dosing-option-for-crysvita-burosumab-twza-in-adults-with-xlh.html

    GLOBENEWSWIRE
    14 May 2026
    Share Share
    CRYSVITA Reimbursed for XLH Adults in Four Canadian Provinces
    CRYSVITA Reimbursed for XLH Adults in Four Canadian Provinces

    06 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/06/3288774/0/en/crysvita-now-publicly-reimbursed-for-the-treatment-of-adults-with-xlh-in-four-provinces-and-federal-non-insured-health-benefits-program.html

    GLOBENEWSWIRE
    06 May 2026
    Share Share
    Ultragenyx Sells Future Crysvita Royalties For $400 Million
    Ultragenyx Sells Future Crysvita Royalties For $400 Million

    04 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/04/3180804/20739/en/Ultragenyx-Announces-Sale-of-a-Portion-of-Future-North-American-Royalties-on-Crysvita-burosumab-for-400-Million-to-OMERS-Life-Sciences.html

    GLOBENEWSWIRE
    04 Nov 2025
    Share Share
    Kyowa Kirin’s Biologics Crysvita Receives Suppl Approval in US
    Kyowa Kirin’s Biologics Crysvita Receives Suppl Approval in US

    28 Aug 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761068

    FDA
    28 Aug 2025
    Share Share
    Kyowa Kirin Responds to NICE’s Publication of Appraisal Document for CRYSVITA
    Kyowa Kirin Responds to NICE’s Publication of Appraisal Document for CRYSVITA

    29 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231128306616/en

    BUSINESSWIRE
    29 Nov 2023
    Share Share
    Kyowa Kirin brings rare disease drug's marketing back in house, future US growth
    Kyowa Kirin brings rare disease drug's marketing back in house, future US growth

    03 May 2023

    // Beth Snyder Bulik ENDPTS

    https://endpts.com/kyowa-kirin-brings-rare-disease-drugs-marketing-back-in-house-plots-future-us-growth/

    Beth Snyder Bulik ENDPTS
    03 May 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.